Related Experiment Video
Updated: Jul 30, 2025

Identifying Coronary Artery Calcification on Non-gated Computed Tomography Scans
Published on: August 28, 2018
Coronary artery calcium among patients with heterozygous familial hypercholesterolaemia
Hayato Tada1, Nobuko Kojima1, Kan Yamagami1
1Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.
Insights
Coronary artery calcium (CAC) scores significantly predict cardiovascular disease (CVD) events in patients with heterozygous familial hypercholesterolaemia (HeFH). Adding CAC to traditional risk factors improves CVD event risk assessment for this high-risk group.
Area of Science:
- Cardiology
- Preventive Medicine
- Medical Imaging
Background:
- Familial hypercholesterolaemia (HeFH) is a genetic disorder leading to high LDL cholesterol and premature cardiovascular disease (CVD).
- Accurate risk stratification is crucial for primary prevention in HeFH patients.
- Coronary artery calcium (CAC) scoring is an established tool for assessing atherosclerosis burden.
Purpose of the Study:
- To investigate the association between CAC scores and the incidence of CVD events in patients with HeFH.
- To evaluate the incremental value of CAC scoring in risk stratification beyond conventional risk factors for HeFH patients.
Main Methods:
- Retrospective analysis of 622 HeFH patients who underwent CAC measurement and were followed for a median of 13.2 years.
- Cox proportional hazard models were used to identify risk factors for CVD events.
- Multivariate analysis assessed the predictive value of log (CAC score + 1) and its impact on risk discrimination.
Main Results:
- A total of 132 CVD events were observed.
- Event rates per 1000 person-years increased significantly with higher CAC scores (1.2 for CAC=0, 17.0 for CAC=1-100, 78.8 for CAC>100).
- Log (CAC score + 1) was an independent predictor of CVD events (HR: 3.24, P < 0.0001), and improved risk discrimination (C-statistics: 0.833-0.934).
Conclusions:
- CAC scoring is a valuable tool for risk stratification in patients with HeFH.
- Incorporating CAC scores enhances the prediction of CVD events in primary prevention settings for HeFH individuals.
- CAC assessment can guide more precise management strategies for HeFH patients at risk of cardiovascular events.
Aims:
We aimed to determine if coronary artery calcium (CAC) is associated with cardiovascular disease (CVD) events, defined as CVD-related death, unstable angina, myocardial infarction, or staged revascularization among patients with heterozygous familial hypercholesterolaemia (HeFH) under primary prevention settings.
Methods And Results:
Data of patients with FH admitted to Kanazawa University Hospital between 2000 and 2020, who underwent CAC measurement and were followed up (n = 622, male = 306, mean age = 54 years), were retrospectively reviewed. Risk factors for CVD events were determined using the Cox proportional hazard model. The median follow-up duration was 13.2 years (interquartile range: 9.8-18.4 years). We observed 132 CVD events during the follow-up period. The event rate per 1000 person-years for CAC scores of 0 [n = 283 (45.5%)], 1-100 [n = 260 (41.8%)], and >100 [n = 79 (12.7%)] was 1.2, 17.0, and 78.8, respectively. Log (CAC score + 1) was a significant predictor of the occurrence of CVD events (hazard ratio: 3.24; 95% confidence interval: 1.68-4.80; P < 0.0001) in the multivariate Cox regression analysis, independent of other factors. The risk discrimination of CVD events was enhanced by adding CAC information to other conventional risk factors (C-statistics: 0.833-0.934; P < 0.0001).
Conclusion:
The CAC score helps in further risk stratification in patients with HeFH.
Related Concept Videos
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease III: Clinical Manifestations

